20 results
To investigate the ability of PF-05089771 to demonstrate analgesic properties in healthy subjects for pre-specified primary endpoints using a panel of pain tests.
To investigate the ability of PF-06273340 to demonstrate analgesic properties in healthy subjects for pre-specified primary endpoints using a panel of pain tests.
The primary objective is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in subjects receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the subject that best…
Determine efficiency and safety of two different doses of pregabalin as compared to placebo.
To examnine the effectiveness of psychological interventions and psychopharmacological interventions compared to placebo-control.
The purpose of the study is to investigate the optimal dose combination of both drugs in healthy volunteers who will undergo a pain test.
The primary goal of this study is to determine if there are any benefits in addition of pregabalin and s-ketamine to local knee infiltration with ropivacaine/adrenaline/kenacort®, regarding the analgesia and the early mobilization in the study group…
Primary objectiveThe primary objective is to evaluate the effectiveness, safety, and tolerability of increasing doses of tapentadol PR (300 mg per day after run in, up titration to 500 mg per day) versus a combination of tapentadol PR (300 mg per…
The objective of this study is to assess the effects of an increased NE level on the trade-off between exploitation and exploration. More specifically, this study will compare the exploitative/explorative behavior of participants who received either…
The primary objective is to examine whether a combined treatment with rivastigmine (cholinesterase inhibitor) and citalopram (selective serotonin re-uptake inhibitor) will improve memory as compared to the treatment with either rivastigmine or…
OBJECTIVESPrimary ObjectiveThe primary objective is to evaluate the efficacy, safety, and tolerability of 800 and 1,200 mg/day of carisbamate compared with placebo in reducing the average daily pain in subjects with diabetic peripheral neuropathy (…
We propose to conduct a study in healthy young and elderly subjects and patients diagnosed with mild to moderate AD, FTLD, or DLB where cholinergic and serotonergic challenges are given in a placebo-controlled, crossover fashion. Before each…
To assess the analgesic efficacy, safety, and tolerability of once daily orally administered cebranopadol in a total of 3 fixed doses (100 µg, 300 µg, and 600 µg cebranopadol) compared to placebo in subjects with moderate to severe chronic pain due…
The primary objective of this study is to evaluate the efficacy of 2 dose levels of pregabalin (Level 1: 2.5 mg/kg/day; maximum 150 mg day and Level 2: 10 mg/kg/day; maximum 600 mg day) compared to placebo as an adjunctive treatment in reducing the…
To assess the effect of citalopram on symptoms of chest pain in patients with functional chest pain.
To examine in depressed patients who reach a stable depression remission during optimal AD treatment: 1) whether discontinuation is possible; 2) when discontinuation is possible; and 3) in whom discontinuation is possible.
To assess the effect of citalopram on chest pain in patients with achalasia and to evaluate the effect of citalopram on esophageal sensitivity.
The objective of the study is to quantify the effect of pregabaline and lacosamide on oxycodone-induced respiratory depression.
Primary• To evaluate the analgesic effects of morphine, pregabalin and the two drugs as combination using PainCartSecondary• To evaluate the drug-sensitive central nervous system (CNS) functioning of morphine, pregabalin and the two drugs as…
The primary objective of this study is to investigate whether pregabalin at a dose of 150-600 mg twice a day reduces pain in patients with chronic neuropathic pain after herniorraphy. This research question will be answered by testing of the…